Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4267226 | 0.91 | CNR1 (0.83) | CNR1GAAPKM | |
| SCHEMBL4273804 | 0.90 | CNR1 (0.82) | CNR1GAAPKMALDH1A1HSP90AA1 | |
| SCHEMBL4269684 | 0.89 | CNR1 (0.80) | CNR1GAAPKM | |
| SCHEMBL4270006 | 0.88 | CNR1 (0.78) | CNR1GAAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL4266704 | 0.88 | CNR1 (0.78) | CNR1ALDH1A1KMT2A | |
| SCHEMBL4270676 | 0.88 | CNR1 (0.78) | CNR1GAAPKMKMT2ASMN1; SMN2 | |
| SCHEMBL4269163 | 0.86 | CNR1 (0.76) | CNR1GAAPKMALDH1A1KMT2A | |
| SCHEMBL4265856 | 0.86 | CNR1 (0.76) | CNR1GAAPKMALDH1A1KMT2A | |
| SCHEMBL4275750 | 0.85 | CNR1 (0.73) | CNR1PKMALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4264796 | 0.84 | CNR1 (1.00) | CNR1GAAPKMALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-10-01 | — | — | US | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-2056828-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247499-A1 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885GAA 1699/4885PKM 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.